Detalhe da pesquisa
1.
Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
BMC Cancer
; 19(1): 60, 2019 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30642291
2.
Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
Eur Urol
; 77(3): 380-387, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31594705
3.
Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study.
JAMA Oncol
; 5(8): 1159-1167, 2019 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31246234
4.
Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study.
ESMO Open
; 3(5): e000397, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30116592